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The list growing and complex field of invasive cardiology
offers a host of opportunities and challenges for the clinician .
Scientific and technical advances ranging front molecular biology
to microtechnology are changing how physicians make decisions
concerning treatment of coronary artery disease, myocardial
Interventional cardiology refers to intravascular, catheter-
mediated procedures that can open, widen or close a vascu-
lar pathway or can stimulate, suppress or ablate electrical
activity of the heart or provide circulatory assistance . The
1993 annual meeting of the American College of Cardiology
held no less than 20 expert panels and 30 meeting sessions
and published nearly 300 abstracts solely on subjects con-
cerned with eardiologic intervention. The field is so enor-
mous and is changing so fast that any "fact" presented here
may already be out of date, and any judgments must be
regarded as tentative .
These interventions fall into two main categories : the
mechanical and the electrical . Among the earliest pervascu-
lar mechanical procedures was atrioseptostomy, developed
by William Rashkind (1) to create an artificial atrial septal
defect in the neonate . This led to other procedures : valvu-
loplasty, percutaneous transluminal coronary angioplasty
(PTCA) and atherectomy, shunt closures and circulatory
assistance, all through catheter techniques .
The era of electrical intervention began with the work of
Furman and Robinson (2), who introduced catheters for
electrical pacing of the heart . This led to the installation,
through the venous system, of permanent, indwelling pace-
makers. All of these procedures led ultimately to the devel-
opment of focal ablation for the treatment of cardiac arrhyth-
mias .
valvUloplasty
The use of catheter-mounted balloons to dilate stenotic
valves has achieved widespread application over the past
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infarction, unstable angina and electrophysiotogic dysfunction .
The economic impact and ethical implications presented by these
developments contribute to the difficulty of achieving optimal
therapeutic solutions for individual patients .
(,f Am Coll Cardiol 1994 ;23,-525-32)
decade . In mitral stenosis the balloons are advanced across
the atrial septum into the stenotic orifice and inflated,
iadudng a satisfactory commissurotomy, with valve areas
often doubling . Results are excellent in centers with ade-
quate experience when patients are carefully selected by
precise clinical and echocardiographic criteria (3,4) . Vil!vu-
loplasty has almost completely replaced surgery for isolated
pulmonary stenosis . Aortic stenosis can be treated with
valvuloplasty, mainly for palliation, particularly in the eld-
erly (5) and in those with advanced noncardiac disease, for
whom surgery is too hazardous (6) . Preference should be
given to surgical therapy when possible, owing to the gen-
erally unsatisfactory or evanescent results of aortic vaivulo-
plasty .
Vascular and Cardiac Occl dens
Catheter-borne closure devices, such as umbrellas, first
developed by King and Mills (7) and Rashkind (8), have now
been produced in sizes large enough to repair patent ductus
arteriosus and atrial and ventricular septal defects . Although
these devices cannot be used in every case, in some circum-
stances they may obviate surgery .
Angioplasty
Although balloon angioplasty currently dominates the
field, the term is used here for any technical means of
widening the coronary artery . The dilation technique origi-
nated with Dotter and Judkins (9), who passed a guide
through the superficial femoral artery and something akin to
a bougie along the guide and through the stenosis (Fig . 1) .
The introduction of the balloon catheter followed, and
angioplasty was soon refined for the peripheral circulation .
The late Andreas Grfintzig (10) had the courage to try it in
coronary artery stenosis . This opened a new era of interven-
tional cardiology (Fig . 2) .
The sophisticated catheters with guide wires, balloons
0735-1097/94/$7 .00
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and pressure delivery and infusion devices have been joined
by the laser beams, shavers, burrs and drills that can be
advanced against an atheroma to ablate it and even remove the
debris. Mason Sones, the father of selective coronary angiog-
raphy, used to speculWkoe that if we were not so chary about
abrading the coronary arteries with the catheter for fear of
producing intimal damage, we could put a Roto-Rooter into
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Figure 1 . A, Spring guide has passed through an occlu-
sion I cm in length. 8, Immediate result of full dilation .
Imt, Patency continues at 8 weeks. Reproduced from
Dotter and iudkins 9 with permission of the American
Heart Association .
them and obliterate these obstructions. Now, 30 years later,
just such devices enable us to do so with reasonable impunity .
Algorithm for angioplasty . The treatment algorithm for
coronary artery disease moves along an arbitrary time line,
beginning with the assessment of clinical needs, moving on
to angiographic assessment and finally to the selection and
implementation of an appropriate intervention .
Figure 2 . Coronary angiography showed
8511/o stenosis of the left anterior descending
coronary artery a . A thallium-201 scan
showed a severe anteroseptal defect after
stress testing . Vessel during and immediately
after dilation b and c . An angiogram taKen 4
weeks after coronary angioplasty showed a
smooth, patent vessel d . The thallium-201
exercise myocardial perfusion scintigram
was normal 6 months after coronary angio-
plasty . Reprinted f.- ,m Griintzig et al . 10 by
permission of the New England Journal of
Medicine, 301 ;61-8, 1979.
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In the clinical assessment one must consider whether the
patient s symptoms justify intervention, whether there is
evidence of inducible myocardial ischemia, whether there
are fixed or reversible perfusion deficits on imaging, the
status of left ventricular function and, finally, patient age .
gender and associated diseases . The latter three attributes
influence both risk and efficacy. This part of the assessment
should be made by a clinical cardiologist, not by the person
who will perform the procedure .
Assessment for coronary angioplasty includes two com-
ponents: the anatomic characteristics of the vessel and
lesion and certain character traits of the angioplaster . The
number of affected arteries and lesions, their location, cali-
ber and tortuosity and whether and where there may be
nearby branches all need to be evaluated . To these variables
mug be added the operator s judgment and experience as
well as a personal, subjective component : The angioplaster
is vulnerable to certain conflicts that could affect the deci-
sion to attempt angioplasty on a given lesion . The physician
is paid for these procedures and may be referring patients to
himself or herself. Finally, personal risk tolerance, although
based partly on experience, will influence the physician s
judgment. How much risk is the practitioner willing to
accept, and at what price, to carry out what may be a difficult
procedure? Dispassionate insight into one s own compe-
tence, confidence in one s ability and awareness of one s
limitations are essential in an angioplaster .
The next issue in assessment for angioplasty is the lesion
itself. Is it soft or hard calcified ? Is it concentric or eccen-
tric? Is it longstanding or of recent origin? These features,
in addition to those already considered, will influence the
choice of a device . There are situations in which an atherec-
tomy device may be preferable to a balloon 11 . The operator
must have experience, know the attributes of the equipment
and be properly trained in its use .
The same caveats apply to stents . Experience in placing
them and understanding how and when to use them are
obviously critical for anyone performing angioplasty .
Results of angioplasty justify its increasingly widespread
use. In New York State for the first half of 1991, 31 hospitals
reported results of procedures in 5,827 patients 12 . This
broad sample ensures that the data represent the norm,
rather than only the best or most experienced operators or
specific referral patterns . The results show rates of 0 .6% for
mortality, 1 .1% for myocardial infarction, 1 .7% for emer-
gency bypass surgery, 3 .2% for overall complications, and
88% for angiographic success . One reason for the good
results is the point in time on a decades-long learning curve .
Before 1991 most interventions were performed on only one
vessel, whereas only 2 years later multiple vessels were
routinely approached with an attendant increase in risk . In
1991 fully 85% of the experience was with single-vessel
angioplasty, with a low mortality rate of 0 .56%. Approxi-
mately 13%, or 700 patients, underwent two-vessel angio-
plasty, with a mortality rate of <I% . Only with three-vessel
or left main coronary artery angioplasty did the mortality
GO!UJN
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figures begin to exceed the results from surgery 1 .9% and
3.7%, respectively .
Coronary angioplasty in acute nmyocardial infarction and
unstable angina . Recent reports suggest that primary angio-
plasty in acute myocardial infarction may be more effective
than thrombolytic therapy 13-16 . In acute myocardial
infarction, angioplasty is most successful when performed 1
early 1 to 2 h from the onset of pain
in the course of a large
anterior infarction, 2 in cardiogenic shock where little else is
effective, 3 when there is unresolved ischemia, and 4 when
thrombolytic therapy is contraindicated . But there are dis-
advantages as well. It is costly . Availability is limited both
nationally and locally . Centers performing angioplasty in the
acute stage of infarction must have a catheterization labora-
tory and nursing and surgical teams on 24-h standby . There
are 900 angioplasty centers nationwide, and the prospect of
equipping them to serve the 3,000 catheterization laborato-
ries and 10,000 coronary care units staggers the imagination .
Recent work indicates that because of the generally shorter
time to intervention, intravenous thrombolysis might be
preferred to coronary angioplasty in acute myocardial infarc-
tion 17 .
The single greatest disadvantage of angioplasty in acute
myocardial infarction is its unpredictability . When success-
ful, the results are good, but if procedural failure or abrupt
vessel closure occurs, the mortality rate becomes unaccept-
able 18 .
Finally, primary angioplasty for unstable angina is still an
open question . Thrombolytic therapy does not appear to e
the answer, and we are not yet certain where primary
angioplasty fits, except in patients with unremitting myocar-
dial ischemia .
Restenosis . Depending on definition and criteria clinical,
angiographic or pharmacologic , resteposis occurs in 30% to
55% of all interventions, irrespective of the technique or
device used, and it poses the key limitation to angioplasty/
atherectomy 19,20 . Restenosis is a reparative process
initiated by the abrupt disruption of the arterial wall, involv-
ing injury and denudation of endothelium and tearing or
cutting of intima, often with extension to the medial layer of
smooth muscle . The response is multifaceted, involving
platelets and white cells attaching to binding molecules in the
intimal and medial layers . There is deposition of fibrin,
preceded by activation of thrombin . Release of growth
factors from a variety of cells leads to extensive constitutive
and induced gene expression for cell growth and migration .
As a consequence, with time, in addition to local platelet-
fibrin-thrombin interaction and adhesion, there is intimal
thickening from proliferation of smooth muscle cells and
conversion of some to fibroblasts . Thus, in 2 to 4 months, a
fibromuscular scar evolves that intrudes on the arterial
!omen but to a highly variable extent .
Restenosis seems particularly aggressive at certain vas-
cular anatomic sites with deep-injury angioplasty lesions and
when the patient has been a smoker or has diabetes or
elevated low density lipoprotein LDL
or lipoprotein a .
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Certain tissue markers found in atherectomy specimens
can predict which patients will have early and exuberant
restenosis 21 , but whatever the physiologic process, the
size of the residual lumen determines whether there will be
significant ischemia . Danchin et al . 22 , from a study of
lumen diameters versus measures of ischemia, state that in
general a final lumen diameter of -2 mm will forestall the
likelihood of myocardial ischemia . Angina or its equivalent
will prompt reexamination of the angioplasty result . The
question is not only whether restenosis has occurred, but
what clinical meaning it has for the patient .
Approaches to restenosis. Mechanical approaches to the
problem of restenosis include excess dilation 23 and stent-
ing 24,25 , whereas pharmacologic and molecular ap-
proaches seek to inhibit platelet attachment, tissue growth
and cell migration .
Mechanical methods . With mechanical dilation, as with
any other, both the immediate and anticipated tong-term
results affect the choice of intervention . The goal is to
achieve a lumen diameter adequate to avoid ischemia . For
example, in keeping with the observation of Danchin et al .,
in a vessel with a stenotic lumen < 1 mm, one will try to
expand it beyond the diameter of the normal vessel wall
segment so that when elastic recoil occurs and tissue over-
growth sets in, a lumen diameter of 2 mm might remain .
There is conflicting evidence that such dilation or debulking,
although permitting a larger short , term postprocedure cross-
sectional area, may result in deeper injury and provoke a
more vigorous proliferative response with similar restenosis
11 .
Pharmacologic methods . Many pharmacologic agents .
ranging from antineoplastic agents 26 to agents for reducing
LDL cholesterol 27 , have been used in an attempt to inhibit
restenosis . For the most part these have been found wanting .
There is some slight evidence that LDL apheresis 28 or the
administration of fish oil 2931 may attenuate the fre-
quency of restenosis Table 1 .
Molecular approaches . A promising and dramatic ap-
proach to diminishing restenosis may be through molecular
biology, Efforts can be targeted at platelets, monocytes,
endothelium or vascular smooth muscle . For example, con-
centrating on vascular smooth muscle the aim is to inhibit
smooth muscle cell growth either by inhibiting growth fac-
tors or receptors in the vascular smooth muscle to which
growth factors attach or by altering the transmembrane
signals that permit growth factors to influence the cell .
Another approach is to inhibit those genes that produce
vascular smooth muscle growth and migration .
Nabel 32 has transferred genetic material directly into
the arterial wall of the Yucatan minipig. Other groups 33
have demonstrated the feasibility of introducing genetic
material directly into the vessel wall using catheters .
Another exciting approach is the so-called gene knockout
using antisense molecules . Simons et al . 34 used an an-
tisense oligonucleotide to inhibit the expression of the proto-
oncogene c-mvb in rat arteries . This resulted in inhibition of
Table 1 . Agents Purported to Impede Restenosis After
Percutaneous Transluminal Coronary Angioplasty
JACC Val. 23, No. 2
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*Possibly effective . LDL = low density lipoprotein
.
smooth muscle cell prolif®ration and the resulting intimal
hyperplasia after balloon injury .
Marmur et at . 35 have used in situ hybridization to
demonstrate expression of tissue factor within vascular
smooth muscle of the media within hours of vessel wall
injury. Taubman M.T., personal communication March
1993 has used an antisense oligonucleotide to block the
expression of tissue factor in smooth muscle cell culture .
This is a prototype for similar work in vivo . These promising
approaches, along with others, may ultimately allow us to
inhibit the excessive proliferative response to vPasel wall
injury and thus control restenosis .
Economic considerations . Initial angioplasty is much less
expensive than bypass surgery Fig. 3 . Although the costs
for the use of a catheterization laboratory or an operating
room are similar, the ensuing hospital stay accounts for the
higher cost in patients undergoing a bypass operation 36 .
The problem with angioplasty is that reintervention adds
enormously to the cost because restenosis occurs in up to
50% of cases 36,37 . Perhaps the unpredictability of angio-
plasty costs could be managed by introducing a 30% to 40%
premium to the initial cost to cover reintervention in that
portion of patients who develop significant restenosis . This
premium could be applied in such a way that future reinter-
ventions would be at no cost to the patient or to the insurer,
a measure that would motivate both the angioplaster and the
nospital to provide the highest quality procedures possible .
The cost of medical therapy versus angioplasty or surgery
for angina pectoris would at first appear to be decisively
advantageous, ranging from $1,000 to $3, /year. But diffi-
culties cloud the issue as time progresses beyond the first
year of any therapy. Patients receiving medical therapy
usually advance symptomatically or do not tolerate therapy
and require coronary angioplasty or revascularization . Sim-
ilarly, late restenosis after angioplasty and diminished graft
patency in patients who have had bypass surgery further
Agent
Study
first author Reference
Colchicine
Antineoplastic R
Ticlopidine, aspirin/
dipyridamole
Coumadin/aspirin
Prostacyclin
O Keefe
Muller et al. 26
White
Thornton
Knudson
J Am Coll Cardiol 1991 ;17:181A
J Am Coll Cardiol 1991 ;17 :1268
Circulation 1987 ;76 :IV-213
Circulation 1984 ;69 :721
Circulation 1986 ;74 :11-282
Nifedipine
Diltiazem
Whiteworth
Corcos
J Am Coll Cardiol 1986 ;8 :1271
Am Heart J 1985 ;109:926
LDL-apheresis*
Fish oil*
Daida
Dehrner
J Am Coll Cardiol 1993 ;21 :34A
N Engi J Med 1988 ;319 :733
Milner Am J Cardic! 1989 ;64 :249
Reis Lancet 1989 ;77 :177
Lovastatin* Sahni Am Heart J 1991 ;121 :1600
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Figure 3 . Proportional contribution of various costs to the total
1-year cost of bypass surgery CABG , coronary angioplasty
PTCA and medical treatment for angina pectoris . Costs are given
in thousands of Dutch guilders Dfl . in 1987 1 DO had an average
value of 0 .49 U.S . dollar. Open bar = reinterventions ; hatched bar
= operating room ; crosshatched bar = hospital stay ; solid bar =
medication . Reprinted, with permission, from van den Brand et al .
36 . © 1990 European Society of Cardiology .
complicate the long-term course of bypass surgery . Along
the way, native artery disease progresses as well . When
judging costs it is critical to weigh the time line when
comparing the options .
Performance standards for angioplasty. When consider-
ing standards for angioplasty, there are three categories to
consider : 1 operator proficiency, experience and case vol-
ume adequate to maintain skills ; 2 clinical and anatomic
guidelines; and 3 ethical principles. When weighing the
clinical anatomic guidelines there must be constant eco-
nomic as well as medical revision . When will medical
therapy alone suffice to alleviate angina or myocardial isch-
emia if improving survival is not the overriding issue? When
can an intervention be delayed without undue risk? Are the
ongoing clinical trials of value?
Comparison Mth medical or surgical therapy. The diffi-
culty of comparing angioplasty with medical or surgical
therapy lies in substratification for the major variables : the
infinite range of vessel pathoanatomy, operator variability
and, finally, selection of a device . Weintraub 38 has re-
pocted registry data from trials comparing bypass surgery
and angioplasty . Mortality, myocardial infarction and 5-year
survival were comparable, but more revascularization pro-
cedures were required after 5 years in those who underwent
angioplasty . Other studies reflect this as well . The random-
ized trial, RITA 37 , reports that bypass surgery and angio-
plasty are comparable with respect to mortality and myocar-
uial infarction . An overwhelming number of patients in the
angioplasty arm, however, required reintervention for re-
Table 2 . AN Success of Percutaneous Trarrslurninal Coronary
Angioplasty in the Randomised Intervention Treatment ol Angina
RITA Trial 510 patients *
*R UA Trial Participants
37
.
stenosis and recurren , -e of myocardial ischemia, even
thou-gh the initial success rate was high Table 2, Fig . 4 .
Preliminary results of the GAB] trial 39 reflect the same
trends. Whatever the advantages of coronary angioplasty
may be, restenosis remains a serious obstacle .
Except for the small ACME trial 40 of isolated disease
of the left anterior descending coronary artery, the clinical
trials do not address how patients receiving optimal medical
treatment with a combination of heta-adrenergic blocking
agents, nitrates and aspirin calcium channel blocking
agents fare compared with those undergoing coronary an-
gioplasty or bypass surgery . Moreover, results of clinical
trials may be confounded by the introduction of new tech-
niques during their course as well as by the current ttndency
to perform multivessel angioplasty . They can, however,
provide overall guidelines to selection of therapy .
Physiologic and anatomic assessment . We need to perform
more physiologic evaluations before carrying out angio-
plasty. Although the angioplaster naturally tends to ap-
proach a lesion as an anatomic obstruction to be disposed of
by technical prowess, the patiLaCS outcome might be better
if we more routinely used intravascular ultrasound imaging
for a better quantitative as well as descriptive anatomy of the
lesion. This should bt coupled with physiologic evaluation of
the significance of any anatomic lesion 41,42 . Lesions that
appear angiographically significant may produce only a
trivial decrease in pressure or Doppler flow velocity, and
response to vasodilators may exhibit virtually normal reac-
tive hyperemia. Such lesions may require no intervention .
Coupling a good physiologic evaluation with our anatomic
studies may improve our long-term success rate with angio-
plasty and help reduce costs through avoidance of unwar-
ranted procedures .
Ethical guidelines . There is an inherent conflict of interest
for both practitioners and hospitals in the performance of
these interventionaI procedures . They are remunerative,
Thus, we must be scrupulously conscientious in ensuring
that we are not performing them to fill our hospital beds and
to support our practices . Self-referral is an obvi ,. u , : ethical
mistake .
Finally, returning to the matter of risk taking, it is crucial
that angioplasters be aware of their own threshold of risk
tolerance and be objective about their own experience and
competence so that decisions can be made only in the best
GORLIN
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Dilations Attempted
no.
Initial Success
%
I vessel
261
90
2 vessels 1 58 S4
3 vessels 47
77
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interest of the patient. This may mean deferring the proce-
dure or refeiring the patient to another interventional phy-
sician .
We must also avoid being driven by the wonders of
technology. There are no fewer than 18 devices for perform-
ing atherectomy alone, as well as catheter devices for other
procedures . It is easy to be seduced by the lure of what we
can do when we ought to be considering what we should do
in the interest of our patients. Unlimited, sweeping use of
these interventions clearly should await our ability to control
the biologic response to injury .
Financial ethics must also govern the use of these proce-
dures. Even with a good initial outcome, increased costs
resulting from reinterventions and from use of these proce-
dures in acute myocardial infarction need to be addressed by
the cardiologic profession before the health care system does
it for us.
Death
	__
1 11 A 2
1
5
Tune since randomisation yr
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Figure 4 . Cumulative risk of later coronary angioplasty
PTCA , bypass surgery CABG , myocardial infarction
MI or death in patients randomized to coronary angio-
plasty top and bypass surgery bottom in the Randomised
Intervention Treatment for Angina RITA trial 37 . Re-
printed with permission from RITA Trial Participants . Cor-
onary angioplasty versus coronary artery bypass surgery :
the Randomised Intervention Treatment of Angina RITA
Trial . Lancet 1993 ; .341 :573-80 . 0 by The Lancet Ltd 1993
.
Ablative Therapy for Arrhythmias
Drug therapy for arrhythmias is often inadequate and
ineffective and may be poorly tolerated. Furthermore, some
drugs are associated with high toxicity, and others have
proarrhythmic effects .
The past 10 to 15 years have seen the emergence of
targued tissue ablation to control arrhythmias through the
elimination of either normal or accessory conduction tracts .
Ablation has also sought to eliminate foci of cctopic impulse
formation . Distal intracoronary injections of necrosing
agents and the application of various forms of electrical
current proved too inexact and too traumatic for cardiac
tissue. The use of radiofrequency energy finally evolved
through the work of Gallagher et al . 43 and Scheinman et
al . 44 . This energy impulse creates a well demarcated,
shallow lesion and has become the technique of choice for
creating a focal lesion at the desired site . This can best be
JACC Vol. 23, No . 2
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seen in selective ablation of the atrioventricular AV node
and certain bypass tracts 43,44 .
Antiarrhythmic drug therapy should be avoided when
possible, particularly in young patients who could be receiv-
ing these agents for life and in patients who are or who
intend to become pregnant . Catheter ablation provides an
opportunity to treat qualifying arrhythmias not only in such
patients but also in those whose condition remains refractory
to drugs. Patients with a rapid ventricular response to atrial
flutter or fibrillation, for which there is no pharmacologic
remedy, can be treated by AV junction ablation and place-
ment of a pacemaker 44,45 . Various bypass tracts leading
to AV node reentry, Wolfs Parkinson-White syndrome and,
finally, certain ventricular tachycardias can now be treated
46-52 .
Experience with 97 patients at The Mount Sinai Medical
Center has yielded a 78% to 10119 success rate in a wide
variety of conditions, with no mortality and only one unin-
tended AV block . Reports from other major centers 45-51
show that these arrhythmias respond well, with a success or
cure rate between 859% and 99% . Complications are rare .
Techniques for avoiding such complications as perforation
and thromboses are improving daily .
Economics of ablative therapy. One year of medical ther-
apy for AV node reentrant tachycardia may cost >$7,600,
resulting from an average of 7.5 visits to the emergency
room, 06 office visits, a few hospitalizations and daily use of
multiple medications 53 . Ablative surgery is eight times
more expensive, whereas radiofrequency ablation by cathe-
ter is only about twice as expensive as medical therapy . The
cost of medical therapy is recovered in 2 years .
Ablation seems to be safe, effective and cost-effective .
Therefore, it should be the primary therapy for certain
supraventricular and ventricular tachycardias .
The future . The future will see continued selective local-
ization and ablation of foci of automaticity or reentry .
Catheter approaches to the atrial arrhythmias to effect the
maze or corridor procedure and to relieve atrial fibrillation or
flutter should be explored . Ventricular arrhythmias other
than those originating in the outflow tract of the right
ventricle are becoming amenable to catheter approaches .
Multiple foci can now be identified and treated . An approach
is needed to the slow conducting tracts that often lie at
varying depths within the ventricular myocardium not easily
accessible by current ablative techniques .
Summary
The field of interventional cardiology represents the ful-
fillment of the cardiologist s perceived manifest destiny to
achieve therapeutic goals through an intravascular pathway
with diminished application of major surgery and even
pharmaceutical agents. We are limited only by the imagina-
tion of the physician and the inventiveness of the microtech-
nologist. In adapting to a constrained health care environ-
GORLIN
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meat the creativity that brought us to interve0onal
cardiology can guide us to cost-effectiveness as well .
Drs. John Ambrose, J
. Anthony Gomes . Davendra Mehta, Mark Taubman,
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of the manuscript
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